Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized Neoantigen Vaccine in Newly Diagnosed, Unmethylated Glioblastoma
NCT04015700Phase 1Active, not recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Jul 2020
- Primary completion
- May 2022
- Modality
- Prophylactic Vaccines, DNA Vaccines, Cancer Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Personalized neoantigen DNA vaccine GNOS-PV01 in glioblastoma (GBM), sponsored by Washington University School of Medicine. Primary endpoints: Dose-limiting Toxicities at 30 days, Number of Participants Who Had Candidate Tumor-specific Neoantigens Identified at 4 weeks and 2 more. Started Jul 2020; status: active, not recruiting.
02
Drugs
Personalized neoantigen DNA vaccine GNOS-PV01
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04015700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04015700.